Creighton UNIVERSITY

Office of the Provost
Research Compliance

CREIGHTON UNIVERSITY
INSTITUTIONAL BIOSAFETY COMMITTEE

IBC MEETING MINUTES

MEETING LOCATION
Zoom (via Invitation)

MEETING DATE and TIME
14-Nov-2025 at 02:00 PM

Institutional Biosafety Committee
2500 California Plaza
Omaha, NE 68178-0125
T: 402.280.2126 | **E:** IBC@creighton.edu
creighton.edu | **creighton.edu/researchservices**

ATTENDANCE

VOTING MEMBERS PRESENT:	
Michael Belshan, PhD Chair, Scientist (Medical Microbiology & Immunology)	**Aurijit Sarkar, PhD** Member, Scientist (Pharmaceutical Sciences)
Richard Goering, PhD Vice Chair, Scientist (Medical Microbiology & Immunology)	**Charles Brockhouse, PhD** Member, Scientist (Biology)
John Baxter Member, Scientist (Biosafety Officer)	**Rima El-Herte, PhD** Member, Scientist (Infectious Disease)
Nicholas Streck, PhD Member, Scientist (Biomedical Sciences, Virology, & Immunology)	**Christopher Austin, MS** Member, Scientist, Community Representative
STAFF MEMBERS PRESENT:	
Teri Prentis, BA *IRB Administrator*	
Stuart Martens, JD *Legal* *Present 2:12 PM-2:14 PM*	
Shannon Walsh, MS *Research Compliance Auditor*	

Attended in Person: None – virtual meeting.
Attended via Zoom: All attendees were present via Zoom.

The IBC has 10 voting members. Six members, including at least one community representative, are required to conduct business.

A quorum was met and Dr. Belshan called the meeting to order at 02:09 PM

The Chair asked whether any members of the Committee had a conflict of interest for any item on the meeting agenda. No members reported a conflict of interest.

The Chair asked whether members of the Committee had received all necessary materials to complete their reviews for this meeting. All members confirmed they received all necessary materials to complete their reviews for this meeting.

The IBC Administrator reviewed the CITI training, documentation, and disclosure requirements for members of the IBC. No members present at this meeting had training, documentation, and/or disclosure deficiencies. All present members were therefore eligible to vote.

The Chair will vote only as necessary to maintain quorum or to break a tie in voting.

REVIEW AND APPROVAL OF PREVIOUS MINUTES

There were no minutes for approval.

REVIEW OF PRIOR BUSINESS

None.

POLICY APPROVALS, ANNOUNCEMENTS, EDUCATION

a. Revised training and documentation requirements

i. Dated CV for the PI only. No longer requiring a signature. All other investigators do not need to upload a CV/résumé.

ii. Removal of Hazard Communication CITI course as the content is covered in the required Lab and Radiation Safety Training created by Mary Duda.

iii. New guidance document for training and documentation requirements has been updated on the public website.

b. New NIH requirements

i. As of June 1, 2025, the NIH requires all approved meeting minutes to be posted on the public website.

a. Minutes that have been approved since the change need to be revised to meet the NIH requirements and will need to be brought back to the Committee for voting.

COMMITTEE REVIEW

Submission Number: EHS-22-0530-07

Title: Development and validation of phenotypic and/or molecular diagnostic methods

Principal Investigator: Nancy Hanson

Submission Type: Continuation

Type of Registration: Infectious Agents Registration

Determination: Approved

Determination Date: 14-Nov-2024

Expiration Date: 16-Oct-2028

Total Vote Count	For	Against	Abstained	Absent	Recused
8	7	0	1	0	0

The Chair, Michael Belshan, abstained.

Agents:	Antibiotic resistant Enterobacteriaceae,

	Pseudomonas spp., Acinetobacter spp, Stenotrophomonas spp., Staphyloccus spp., Streptococcus spp., Burkolderia spp., Neisseria spp., and anaerobic oral flora such as Porphyromonas gingivalis, Tannerella spp., and Fusobacterium spp.
Agent Risk Group:	RG-2
NIH Guidelines category of r/s NA research, if applicable:	N/A

Summary: The organisms listed will be used to develop and/or validate diagnostic tests for phenotypic and/or molecular identification of resistance mechanisms. The organisms are plated on both selective and non-selective media for growth and when molecular diagnostic tests are being developed or validated DNA, RNA, or protein may be extracted from the organisms and evaluated with methods such as PCR, sequence analysis, or westerns.

Some organisms listed are part of the CDC-FDA panel specially designed by these agencies for the validation of these types of diagnostic tests. There is little potential for biohazard concerns as these are all BSL-2 level organisms.

Organisms grown in broth and/or solid media will be killed by autoclaving those media when the experiment has concluded. Gloves and lab coats are used to protect from any spills that may occur and 10% bleach or 70% alcohol will be used to clean up any surface spills that might occur during handling of bacterial cultures.

Discussion: The Chair provided the opportunity for discussion. No discussion was had regarding this submission. The Committee voted to approve the continuation as written.

All required training per institutional policy is complete for all individuals listed on this registration.

PUBLIC COMMENTS

There were no public comments.

THIS MEETING ADJOURNED AT 02:14 PM

END OF COMMITTEE REVIEW

Next meeting is tentatively scheduled for 19-Dec-2025 at 2 PM.

END REPORT